NICE approves Amryt's Myalepta for reimbursement in England and Wales
Commercial-stage biopharmaceutical company Amryt Pharma announced on Wednesday that the National Institute for Health and Care Excellence (NICE) has approved ‘Myalepta’, or metreleptin, for reimbursement in England and Wales.
The AIM-traded firm said the reimbursement approval was for the use of Myalepta as an adjunct to diet as replacement therapy for the treatment of leptin deficiency in patients with congenital or acquired general lipodystrophy in adults and children two years of age and above, and familial or acquired partial lipodystrophy in adults and children 12 years of age and above.
Myalepta received marketing authorisation from the European Medicines Agency in 2018.
“We are very excited to report NICE’s approval of Myalepta which will now give all England and Wales based patients suffering from lipodystrophy the opportunity to access Myalepta,” said chief executive officer Dr Joe Wiley.
“Today’s news represents further progress in our efforts to grow the geographic reach of our commercial products in both existing and new territories.”
At 1241 GMT, shares in Amryt Pharma were up 2.36% at 199.6p.